Mittie Doyle, the Chief Medical Officer of $AVTX, sold 679 shares of the company on 04-01-2026 for an estimated $10,864. We received data on the trade from a recent SEC filing. This was a sale of approximately 15.8% of their shares of this class of stock. Following this trade, they now own 3,622 shares of this class of $AVTX stock.
$AVTX Insider Trading Activity
$AVTX insiders have traded $AVTX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $AVTX stock by insiders over the last 6 months:
- MITTIE DOYLE (Chief Medical Officer) has made 0 purchases and 2 sales selling 26,171 shares for an estimated $422,470.
- JONATHAN GOLDMAN has made 0 purchases and 2 sales selling 11,367 shares for an estimated $162,936.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AVTX Hedge Fund Activity
We have seen 58 institutional investors add shares of $AVTX stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 522,548 shares (+380.2%) to their portfolio in Q4 2025, for an estimated $9,489,471
- JENNISON ASSOCIATES LLC added 475,625 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,637,350
- MARSHALL WACE, LLP added 451,541 shares (+806.2%) to their portfolio in Q4 2025, for an estimated $8,199,984
- SOLEUS CAPITAL MANAGEMENT, L.P. added 441,978 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,026,320
- UBS GROUP AG added 432,608 shares (+956.9%) to their portfolio in Q4 2025, for an estimated $7,856,161
- POINT72 ASSET MANAGEMENT, L.P. removed 426,481 shares (-40.5%) from their portfolio in Q4 2025, for an estimated $7,744,894
- BALYASNY ASSET MANAGEMENT L.P. removed 378,124 shares (-46.3%) from their portfolio in Q4 2025, for an estimated $6,866,731
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AVTX Revenue
$AVTX had revenues of $59K in Q4 2025. This is a decrease of -69.27% from the same period in the prior year.
You can track AVTX financials on Quiver Quantitative's AVTX stock page.
$AVTX Analyst Ratings
Wall Street analysts have issued reports on $AVTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 03/24/2026
- Guggenheim issued a "Buy" rating on 02/02/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/15/2026
- Mizuho issued a "Outperform" rating on 12/18/2025
To track analyst ratings and price targets for $AVTX, check out Quiver Quantitative's $AVTX forecast page.
$AVTX Price Targets
Multiple analysts have issued price targets for $AVTX recently. We have seen 4 analysts offer price targets for $AVTX in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $40.0 on 03/25/2026
- Julian Harrison from BTIG set a target price of $40.0 on 03/24/2026
- Yatin Suneja from Guggenheim set a target price of $50.0 on 02/02/2026
- Joseph Catanzaro from Mizuho set a target price of $39.0 on 12/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
